TKNO Alpha Teknova, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1850902 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.4%
TTM net income YoY12.3%
TTM EPS YoY9.1%
Revenue 3-yr CAGR7.8%
Net income 3-yr CAGR—
Margins
Gross margin36.4%
Operating margin-32.7%
Net margin-34.8%
FCF margin-13.9%
EBITDA margin-20.1%
Returns
ROE-24.1%
ROA-15.8%
ROIC (approx.)-15.9%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets36.9%
Debt / equity0.22x
Current ratio3.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-10.3%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $40.52M | $37.74M | $36.68M | $41.42M | $36.89M |
| Cost of revenue | $27.08M | $30.51M | $26.39M | $23.94M | $19.27M |
| Gross profit | $13.44M | $7.23M | $10.30M | $17.48M | $17.62M |
| R&D expense | $2.20M | $2.76M | $5.57M | $7.74M | $4.31M |
| SG&A expense | $20.32M | $23.15M | $25.45M | $28.30M | $20.39M |
| Operating income | -$16.98M | -$26.15M | -$35.56M | -$49.66M | -$12.01M |
| Pretax income | -$17.20M | -$26.83M | -$37.08M | -$49.39M | -$12.64M |
| Income tax | $58,000 | -$88,000 | -$298,000 | -$1.92M | -$2.83M |
| Net income | -$17.26M | -$26.75M | -$36.78M | -$47.47M | -$9.80M |
| EBITDA | -$10.63M | -$19.57M | -$29.90M | -$45.16M | -$9.12M |
| EPS (basic) | -0.32 | -0.57 | -1.16 | -1.69 | -0.61 |
| EPS (diluted) | -0.32 | -0.57 | -1.16 | -1.69 | -0.61 |
| Weighted avg. shares (diluted) | 53.48M | 46.75M | 31.82M | 28.08M | 16.09M |
| Banking | |||||
| Net interest income | -$710,000 | -$687,000 | -$833,000 | $213,000 | -$589,000 |
| Balance sheet | |||||
| Cash & equivalents | $5.91M | $3.71M | $28.48M | $42.24M | $87.52M |
| Short-term investments | $15.43M | $26.69M | $0 | — | $0 |
| Receivables | $4.62M | $4.31M | $3.95M | $4.26M | $4.67M |
| Inventory | $7.05M | $6.80M | $11.59M | $12.25M | $5.39M |
| Current assets | $34.51M | $42.78M | $45.66M | $61.14M | $101.20M |
| PP&E, net | $41.73M | $45.75M | $50.36M | $51.58M | $29.81M |
| Goodwill | — | — | — | $0 | $16.61M |
| Intangibles | $11.94M | $13.09M | $14.24M | $17.56M | $18.70M |
| Total assets | $103.58M | $118.77M | $128.59M | $152.26M | $166.51M |
| Current liabilities | $7.54M | $11.21M | $8.88M | $10.88M | $7.74M |
| Short-term debt | $0 | $4.04M | $0 | $0 | — |
| Long-term debt | $13.12M | $9.44M | $13.25M | $21.98M | $11.87M |
| Total debt | $13.12M | $13.49M | $13.25M | $21.98M | $11.87M |
| Total liabilities | $34.81M | $36.38M | $38.55M | $52.38M | $23.31M |
| Shareholders' equity | $68.78M | $82.39M | $90.04M | $99.89M | $143.20M |
| Net debt | $7.21M | $9.78M | -$15.23M | -$20.26M | -$75.65M |
| Shares outstanding | 53.56M | 53.41M | 40.79M | 28.18M | 28.01M |
| Cash flow statement | |||||
| Operating cash flow | -$8.65M | -$12.39M | -$18.81M | -$27.40M | -$9.07M |
| Capital expenditure | $1.15M | $1.12M | $7.93M | $28.15M | $19.88M |
| Free cash flow | -$9.79M | -$13.52M | -$26.75M | -$55.55M | -$28.95M |
| Investing cash flow | $10.70M | -$27.27M | -$7.74M | -$28.15M | -$17.52M |
| Financing cash flow | $151,000 | $14.89M | $12.80M | $10.27M | $110.79M |
| Depreciation & amortization | $6.34M | $6.58M | $5.66M | $4.50M | $2.88M |
| Stock-based compensation | $3.43M | $3.67M | $4.14M | $3.71M | $1.55M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.